Stock Financial Ratios, Dividends, Split History

TXMD / TherapeuticsMD, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price5.61
Volume1,297,800.00
Market Cap ($M)1,235.87
Enterprise Value ($M)1,229.38
Book Value ($M)129.91
Book Value / Share0.60
Price / Book9.46
NCAV ($M)139.55
NCAV / Share0.64
Price / NCAV8.70
Income Statement (mra) ($M)
Revenue16.78
EBITDA-77.63
Net Income-76.93
Balance Sheet (mrq) ($M)
Cash & Equivalents0.00
Cash / Share0.00
Assets143.23
Liabilities13.32
Quick Ratio10.36
Current Ratio10.48
Share Statistics
Common Shares Outstanding216,439,483
Common Stock Shares Outstanding216,429,642
Preferred Stock Shares Outstanding0
Scoring Models
Piotroski F-Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.59
Return on Assets (ROA)-0.54
Return on Equity (ROE)-0.60
Identifiers and Descriptors
CUSIP88338N107
Central Index Key (CIK)25743
Industry Groups
SIC 2834 - Pharmaceutical Preparations
Related CUSIPS
88338N907 88338N957

Split History

Stock splits are used by TherapeuticsMD, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Peers - Pharmaceutical Preparations (2834)

TXMD: TherapeuticsMD Analysis and Research Report

2018-02-26 - Asif

TherapeuticsMD was incorporated in Utah in 1907 under the name Croff Mining Company, or Croff. Prior to 2008, Croff’s operations consisted entirely of oil and natural gas leases. Due to a spin-off of its operations in December 2007, Croff had no business operations or revenue source and had reduced its operations to a minimal level although it continued to file reports required under the Securities Exchange Act of 1934, or the Exchange Act. As a result of the spin-off, Croff was a “shell company” under the rules of the Securities and Exchange Commission, or the SEC. In July 2009, Croff (i) closed a transaction to acquire America’s Minority Health Network, Inc. as a wholly owned subsidiary, (ii) ceased being a shell company, and (iii) experienced a change in control in which the former stockholders of America’s Minority Health Network, Inc. acquired control of its company. On June 11, 2010, the company closed a transaction to acquire Spectrum Health Network, Inc. as a wholly owned subsi...

Related Articles

GNCA: Genocea Biosciences Analysis and Research Report

11h - Asif

Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...

AMZN: Amazon.com, Inc Analysis and Research Report

11h - Asif

Overview Amazon.com opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...

LPCN: Lipocine Inc Analysis and Research Report

2018-04-23 - Asif

Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...

Related News Stories

Your Daily Pharma Scoop: Immuron Surges, MyoKardia Results, Voyager Reports Longer-Term Data For VY-AADC

2018-03-10 seekingalpha
Today, we will discuss Immuron (IMRN) focusing on the results announced from a phase 2 proof-of-concept study evaluating IMM-124E in 133 NASH patients. The announcement sparked a huge rally in IMRN shares, which closed nearly 62% higher in the U.S. (54-4)

Biotech Forum Daily Digest For March 9th

2018-03-09 seekingalpha
Both the overall market and the main biotech indices managed a slight gain Thursday as new proposed tariffs were better than the worse case scenario. (93-0)

BRIEF-TherapeuticsMD Announces FDA Acceptance Of New Drug Application For Tx-001Hr

2018-03-08 reuters
* THERAPEUTICSMD ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION (NDA) AND PRESCRIPTION DRUG USER FEE ACT (PDUFA) DATE FOR TX-001HR (2-0)

TherapeuticsMD: Debt Financing Delay

2018-02-23 seekingalpha
TherapeuticsMD (TXMD) just has its Q4 conference call. The main takeaway is debt financing has been delayed from Q1 to early Q2. This is indeed a cause for concern pointing to potential roadblocks to financing and might lead to an equity raise. However, investors should still remain bullish about the company. (2-4)

TherapeuticsMD's (TXMD) CEO Robert Finizio on Q4 2017 Results - Earnings Call Transcript

2018-02-21 seekingalpha
Good morning, ladies and gentlemen, thank you for joining us for the TherapeuticsMD Fourth Quarter and Full-Year 2017 Financial Results Conference Call. Following prepared remarks from the Company, we will open the call for questions. (18-2)

CUSIP: 88338N107